ArticleFungal genetics and biology : FG & B2020
In the fungus where it happens: History and future propelling Aspergillus nidulans as the archetype of natural products research.
Article in Fungal genetics and biology : FG & B, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 63 citations in OpenAlex.
- Article
- Discovery of a dimeric isopimarane derivative by reexploring a labdane-related diterpenoid biosynthetic gene cluster in Aspergillus nidulans.Microbial cell factories · 2026Article
- Heterologous Expression Unexpectedly Activates the Host Cryptic Genes inJournal of fungi (Basel, Switzerland) · 2026Article
- Advances in molecular tools for elucidating nucleic acid biology in fungal pathogens.microLife · 2026Review
- The regulatory network ofMicrobiology spectrum · 2025Article
- Confrontations of the Pathogenic Fungus Colletotrichum graminicola With a Biocontrol Bacterium or a Ubiquitous Fungus Trigger Synthesis of Secondary Metabolites With Lead Structures of Synthetic Fungicides.Environmental microbiology · 2025Article
- Microbial secondary metabolites: advancements to accelerate discovery towards application.Nature reviews. Microbiology · 2025Review
- Considerations for Domestication of Novel Strains of Filamentous Fungi.ACS synthetic biology · 2025Review
- Next-generation AMA1-based plasmids for enhanced heterologous expression in filamentous fungi.Microbial biotechnology · 2024Article
- Construction of an expression platform for fungal secondary metabolite biosynthesis in Penicillium crustosum.Applied microbiology and biotechnology · 2024Article
- Article
- A Timeline of Biosynthetic Gene Cluster Discovery inJournal of fungi (Basel, Switzerland) · 2024Article
- Terpenoid balance inScience advances · 2024Article
- Improved gene editing and fluorescent-protein tagging inWellcome open research · 2024Article
- A novel aromatic compound from the fungus Synnemellisia sp. FKR-0921.The Journal of antibiotics · 2023Article
- Terpenoid balance inbioRxiv : the preprint server for biology · 2023Article
- A heterologous expression platform inChemical science · 2023Article
- Mining for a new class of fungal natural products: the evolution, diversity, and distribution of isocyanide synthase biosynthetic gene clusters.Nucleic acids research · 2023Article
- Production of L-Malic Acid by Metabolically EngineeredJournal of fungi (Basel, Switzerland) · 2023Article
- Mining for a New Class of Fungal Natural Products: The Evolution, Diversity, and Distribution of Isocyanide Synthase Biosynthetic Gene Clusters.bioRxiv : the preprint server for biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
In 1990 the first fungal secondary metabolite biosynthetic gene was cloned in Aspergillus nidulans. Thirty years later, >30 biosynthetic gene clusters (BGCs) have been linked to specific natural products in this one fungal species. While impressive, over half of the BGCs in A. nidulans remain uncharacterized and their compounds structurally and functionally unknown. Here, we provide a comprehensive review of past advances that have enabled A. nidulans to rise to its current status as a natural product powerhouse focusing on the discovery and annotation of secondary metabolite clusters. From genome sequencing, heterologous expression, and metabolomics to CRISPR and epigenetic manipulations, we present a guided tour through the evolution of technologies developed and utilized in the last 30 years. These insights provide perspective to future efforts to fully unlock the biosynthetic potential of A. nidulans and, by extension, the potential of other filamentous fungi.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.